Fereshteh Ghiasvand
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Fereshteh Ghiasvand has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Fatemeh Jafari
School of Medicine Iran University of Medical Sciences Tehran Iran
5 shared publications- SeyedAhmad SeyedAlinaghi
Iranian Research Center for HIV/AIDS (IRCHA), Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran
5 shared publications Zahra Ahmadinejad
Liver Transplantation Research Center, Department of Infectious Diseases, Imam Khomeini Hospital Complex Tehran University of Medical Sciences Tehran Iran
5 shared publications- Malihe Hasannezhad
Department of Infectious Diseases and Tropical Medicine Tehran University of Medical Sciences, Imam Khomeini Hospital Complex Tehran Iran
4 shared publications - Maryam Moradi
Eye Research Center, The Five Senses Health Institute, Rassoul Akram Hospital Iran University of Medical Sciences Tehran Iran
4 shared publications Mohamadreza Salehi
Infectious Disease Research Institute
4 shared publications
Latest Publications
- Open Access
- 31 January 2024
- Published by Wiley
Bilateral spontaneous pneumothorax as a late complication of COVID-19, a case report
The first case of sever pneumonia caused by coronavirus (COVID-19) was detected in Wuhan, China in December 2019 and spread rapidly around the world. Pneumothorax has been reported as an uncommon complication following COVID-19 infection which caused by alveolar rupture, air leakage and interstitial emphysema after alveolar damages. Bilateral pneumothorax is also an uncommon life threatening complication induced by COVID-19 which has to be considered in patients present with late sudden dyspnea after Coronavirus infection. In this case report, we are presenting a patient with mild COVID-19 pneumonia with a left massive pneumothorax following a late sudden dyspnea in third week of the disease, during the hospitalization, in addition to aggravating the respiratory condition, right pneumothorax was also added.
- 31 January 2024
- Published by Wiley
Open AccessBilateral spontaneous pneumothorax as a late complication of COVID-19, a case report
The first case of sever pneumonia caused by coronavirus (COVID-19) was detected in Wuhan, China in December 2019 and spread rapidly around the world. Pneumothorax has been reported as an uncommon complication following COVID-19 infection which caused by alveolar rupture, air leakage and interstitial emphysema after alveolar damages. Bilateral pneumothorax is also an uncommon life threatening complication induced by COVID-19 which has to be considered in patients present with late sudden dyspnea after Coronavirus infection. In this case report, we are presenting a patient with mild COVID-19 pneumonia with a left massive pneumothorax following a late sudden dyspnea in third week of the disease, during the hospitalization, in addition to aggravating the respiratory condition, right pneumothorax was also added.
- Open Access
- 31 January 2024
- Published by Wiley
Outcome of using Intravenous Immunoglobulin (IVIG) in critically ill COVID-19 patients’: a retrospective, multi-centric cohort study
Background: To access the effect of Intravenous immunoglobulin (IVIG) in critically ill corona virus disease 2019 (COVID-19) patients. Method: In this retrospective matched cohort study, records of three tertiary centers with large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using independent t-test and One-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate. Result: The duration of hospitalization in the IVIG group were significantly longer than standard treatment (13.74 days vs. 11.10 days, p0.05). Also initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (P<0.01). Conclusion: Using IVIG is not beneficial for COVID-19 patients based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation and even mortality rate.
- 31 January 2024
- Published by Wiley
Open AccessOutcome of using Intravenous Immunoglobulin (IVIG) in critically ill COVID-19 patients’: a retrospective, multi-centric cohort study
Background: To access the effect of Intravenous immunoglobulin (IVIG) in critically ill corona virus disease 2019 (COVID-19) patients. Method: In this retrospective matched cohort study, records of three tertiary centers with large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using independent t-test and One-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate. Result: The duration of hospitalization in the IVIG group were significantly longer than standard treatment (13.74 days vs. 11.10 days, p0.05). Also initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (P<0.01). Conclusion: Using IVIG is not beneficial for COVID-19 patients based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation and even mortality rate.
- Open Access
- 10 January 2023
- Published by Wiley
Recurrent culture-negative endocarditis and osteomyelitis caused by Q fever in Iran, a case report.
In this case report, we are presenting a man with intermittent fever for three months with a history of aortic and pulmonary valve replacement and also recurrent blood culture-negative endocarditis. After several evaluations based on endemic epidemiology, the Real-time PCR and IFA (indirect immunofluorescence assay) were positive for Q fever.
- 10 January 2023
- Published by Wiley
Open AccessRecurrent culture-negative endocarditis and osteomyelitis caused by Q fever in Iran, a case report.
In this case report, we are presenting a man with intermittent fever for three months with a history of aortic and pulmonary valve replacement and also recurrent blood culture-negative endocarditis. After several evaluations based on endemic epidemiology, the Real-time PCR and IFA (indirect immunofluorescence assay) were positive for Q fever.
- Open Access
- 3 January 2023
- Published by Wiley
Bilateral spontaneous pneumothorax as a late complication of COVID-19, a clinical case report
Bilateral spontaneous pneumothorax can occur as a late complication in patients with COVID-19 even without any history of mechanical ventilation. Here, we are presenting a patient with mild COVID-19 pneumonia with a left massive pneumothorax in the third week of the hospitalization, and the addition of right pneumothorax as well.
- 3 January 2023
- Published by Wiley
Open AccessBilateral spontaneous pneumothorax as a late complication of COVID-19, a clinical case report
Bilateral spontaneous pneumothorax can occur as a late complication in patients with COVID-19 even without any history of mechanical ventilation. Here, we are presenting a patient with mild COVID-19 pneumonia with a left massive pneumothorax in the third week of the hospitalization, and the addition of right pneumothorax as well.
- Open Access
- 2 March 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 16 (5)
COVID-19 Reinfection or Relapse? A Retrospective Multicenter Cohort Study from Iran
Background: Returning symptomatic patients with a history of recovered COVID-19 with a new positive SARS CoV-2 PCR test after several weeks to months of a negative PCR result is challenging during the COVID-19 pandemic. Objectives: We aimed to determine such Iranian patients' clinical and laboratory characteristics and discuss possible reasons. Methods: We retrospectively investigated SARS CoV-2 PCR tests in three referral hospitals. All patients who had the following criteria were included in the study: two SARS CoV-2 PCR-positive tests three months apart, no symptoms, a negative PCR test between the two positive tests, and access to the patient and medical information. Then, we retrospectively recorded the clinical and laboratory characteristics of the eligible patients. We also compared the clinical and laboratory features in the first and second episodes. Results: Among 1,899 patients, 37 cases were eligible in the study based on our criteria. The majority of patients were males and nurses. The mean age was 37.54 ± 15.16 years. Weakness, myalgia, and fever were the most frequent clinical symptoms in both episodes. The mean interval between discharge and second presentation was 117 ± 61.42 days. The clinical, radiological, and laboratory characteristics were not significantly different between the two episodes, except for significantly more dexamethasone use in the second episode (P = 0.03). Conclusions: We could not cultivate the virus and perform the phylogenic sequencing of SARS-CoV-2; however, the prolonged interval between the two episodes suggests probable reinfection in our cases. Finally, this clinical phenomenon may be more common in HCW without a significant consequence; however, most cases were HCW who had more compatibility with our criteria due to the availability of their medical information.
- 2 March 2022
- Published by Brieflands in Archives of Clinical Infectious Diseases
- Vol. 16 (5)
Open AccessCOVID-19 Reinfection or Relapse? A Retrospective Multicenter Cohort Study from Iran
Background: Returning symptomatic patients with a history of recovered COVID-19 with a new positive SARS CoV-2 PCR test after several weeks to months of a negative PCR result is challenging during the COVID-19 pandemic. Objectives: We aimed to determine such Iranian patients' clinical and laboratory characteristics and discuss possible reasons. Methods: We retrospectively investigated SARS CoV-2 PCR tests in three referral hospitals. All patients who had the following criteria were included in the study: two SARS CoV-2 PCR-positive tests three months apart, no symptoms, a negative PCR test between the two positive tests, and access to the patient and medical information. Then, we retrospectively recorded the clinical and laboratory characteristics of the eligible patients. We also compared the clinical and laboratory features in the first and second episodes. Results: Among 1,899 patients, 37 cases were eligible in the study based on our criteria. The majority of patients were males and nurses. The mean age was 37.54 ± 15.16 years. Weakness, myalgia, and fever were the most frequent clinical symptoms in both episodes. The mean interval between discharge and second presentation was 117 ± 61.42 days. The clinical, radiological, and laboratory characteristics were not significantly different between the two episodes, except for significantly more dexamethasone use in the second episode (P = 0.03). Conclusions: We could not cultivate the virus and perform the phylogenic sequencing of SARS-CoV-2; however, the prolonged interval between the two episodes suggests probable reinfection in our cases. Finally, this clinical phenomenon may be more common in HCW without a significant consequence; however, most cases were HCW who had more compatibility with our criteria due to the availability of their medical information.
- Open Access
- 3 February 2022
- Published by Springer Nature in European Journal of Medical Research
- Vol. 27 (1) , 1-8
The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients’: a retrospective, multi-centric cohort study
Background: During the COVID-19 pandemic, different treatments have been used in critically ill patients. Using intravenous immunoglobulin (IVIG) has been suggested in various studies as an effective option. Our study aims to access the efficacy of IVIG in critically ill COVID-19 patients. Methods: In this retrospective matched cohort study, records of three tertiary centers with a large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using an independent t test and one-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate. Results: The duration of hospitalization in the IVIG group was significantly longer than standard treatment (13.74 days vs. 11.10 days, p < 0.05). There was no significant difference between the two groups in ICU length of stay, the number of intubated patients, and duration of mechanical ventilation (p > 0.05). Also, initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (p < 0.01). Conclusion: Our data indicate that the use of IVIG in critically ill COVID-19 patients could not be beneficial, based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation, and even mortality rate.
- 3 February 2022
- Published by Springer Nature in European Journal of Medical Research
- Vol. 27 (1) , 1-8
Open AccessThe outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients’: a retrospective, multi-centric cohort study
Background: During the COVID-19 pandemic, different treatments have been used in critically ill patients. Using intravenous immunoglobulin (IVIG) has been suggested in various studies as an effective option. Our study aims to access the efficacy of IVIG in critically ill COVID-19 patients. Methods: In this retrospective matched cohort study, records of three tertiary centers with a large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using an independent t test and one-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate. Results: The duration of hospitalization in the IVIG group was significantly longer than standard treatment (13.74 days vs. 11.10 days, p < 0.05). There was no significant difference between the two groups in ICU length of stay, the number of intubated patients, and duration of mechanical ventilation (p > 0.05). Also, initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (p < 0.01). Conclusion: Our data indicate that the use of IVIG in critically ill COVID-19 patients could not be beneficial, based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation, and even mortality rate.
- 26 December 2021
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 28 (3) , 424-433
Comparing two equations for estimation of kidney function (Cockcroft-Gault and Glomerular Filtration Rate Assessment in Liver Disease) for vancomycin dosing in adult liver transplant recipients: a pilot, randomized clinical trial
Background: In the setting of impaired liver function, estimation of glomerular filtration rate (GFR) using common creatinine-based equations is inaccurate. Recently, the Glomerular filtration Rate Assessment In Liver disease (GRAIL) model has been introduced to estimate GFR in liver transplantation. This study was conducted to compare vancomycin dose adjustment in liver transplant patients using Cockcroft-Gault (C-G) versus the GRAIL method. Methods: In this pilot, randomized clinical trial, adult liver transplant recipients who were a candidate to receive intravenous vancomycin were enrolled. The level of kidney function was estimated using the GRAIL model and C-G equation in the intervention and control arms, respectively. Then, vancomycin maintenance doses were accordingly adjusted. At the steady state, peak and trough serum concentrations of vancomycin were collected for area under the concentration-time curve (AUC) calculation and pharmacokinetic comparisons. Results: Fifteen patients were enrolled in each arm of study. The mean daily dose of vancomycin was estimated insignificantly lower for individuals in the GRAIL arm than the C-G group (1550.00±544.45 versus 1750.00± 389.60mg). Compared with the C-G group, a higher rate of patients in the GRAIL arm experienced below-target vancomycin trough concentrations (40.0% versus 13.3%), and a lower rate showed above target trough concentration (40.0% versus 66.7%). These differences did not reach statistical significance. Individuals in the GRAIL arm represented significantly higher rate of below target vancomycin AUC/MIC than patients in the C-G arm (46.7% versus 6.7%) (P=0.049). No differences in clinical outcomes were observed between the two groups. Conclusion: Using the GRAIL model for vancomycin dosing may result in less percent of patients with at target AUC/MIC compared to the C-G method and expose more patients at risk for vancomycin under dosing.
- 26 December 2021
- Published by Maad Rayan Publishing Company in Pharmaceutical Sciences
- Vol. 28 (3) , 424-433
Comparing two equations for estimation of kidney function (Cockcroft-Gault and Glomerular Filtration Rate Assessment in Liver Disease) for vancomycin dosing in adult liver transplant recipients: a pilot, randomized clinical trial
Background: In the setting of impaired liver function, estimation of glomerular filtration rate (GFR) using common creatinine-based equations is inaccurate. Recently, the Glomerular filtration Rate Assessment In Liver disease (GRAIL) model has been introduced to estimate GFR in liver transplantation. This study was conducted to compare vancomycin dose adjustment in liver transplant patients using Cockcroft-Gault (C-G) versus the GRAIL method. Methods: In this pilot, randomized clinical trial, adult liver transplant recipients who were a candidate to receive intravenous vancomycin were enrolled. The level of kidney function was estimated using the GRAIL model and C-G equation in the intervention and control arms, respectively. Then, vancomycin maintenance doses were accordingly adjusted. At the steady state, peak and trough serum concentrations of vancomycin were collected for area under the concentration-time curve (AUC) calculation and pharmacokinetic comparisons. Results: Fifteen patients were enrolled in each arm of study. The mean daily dose of vancomycin was estimated insignificantly lower for individuals in the GRAIL arm than the C-G group (1550.00±544.45 versus 1750.00± 389.60mg). Compared with the C-G group, a higher rate of patients in the GRAIL arm experienced below-target vancomycin trough concentrations (40.0% versus 13.3%), and a lower rate showed above target trough concentration (40.0% versus 66.7%). These differences did not reach statistical significance. Individuals in the GRAIL arm represented significantly higher rate of below target vancomycin AUC/MIC than patients in the C-G arm (46.7% versus 6.7%) (P=0.049). No differences in clinical outcomes were observed between the two groups. Conclusion: Using the GRAIL model for vancomycin dosing may result in less percent of patients with at target AUC/MIC compared to the C-G method and expose more patients at risk for vancomycin under dosing.
- 27 November 2021
- Published by Springer Nature in Pharmacological Reports
- Vol. 74 (1) , 229-240
Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial
Background and objectives Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients with a diagnosis of moderate to severe COVID-19. Methods Hospitalized patients with a diagnosis of moderate to severe COVID-19 were assigned to intravenous low-dose (8 mg once daily), intermediate-dose (8 mg twice daily) or high-dose (8 mg thrice daily) dexamethasone for up to 10 days or until hospital discharge. Clinical response, 60-day survival and adverse effects were the main outcomes of the study. Results In the competing risk survival analysis, patients in the low-dose group had a higher clinical response than the high-dose group when considering death as a competing risk (HR = 2.03, 95% CI: 1.23–3.33, p = 0.03). Also, the survival was significantly longer in the low-dose group than the high-dose group (HR = 0.36, 95% CI = 0.15–0.83, p = 0.02). Leukocytosis and hyperglycemia were the most common side effects of dexamethasone. Although the incidence was not significantly different between the groups, some adverse effects were numerically higher in the intermediate-dose and high-dose groups than in the low-dose group. Conclusions Higher doses of dexamethasone not only failed to improve efficacy but also resulted in an increase in the number of adverse events and worsen survival in hospitalized patients with moderate to severe COVID-19 compared to the low-dose dexamethasone. (IRCT20100228003449N31).
- 27 November 2021
- Published by Springer Nature in Pharmacological Reports
- Vol. 74 (1) , 229-240
Comparing efficacy and safety of different doses of dexamethasone in the treatment of COVID-19: a three-arm randomized clinical trial
Background and objectives Corticosteroids are commonly used in the treatment of hospitalized patients with COVID-19. The goals of the present study were to compare the efficacy and safety of different doses of dexamethasone in the treatment of patients with a diagnosis of moderate to severe COVID-19. Methods Hospitalized patients with a diagnosis of moderate to severe COVID-19 were assigned to intravenous low-dose (8 mg once daily), intermediate-dose (8 mg twice daily) or high-dose (8 mg thrice daily) dexamethasone for up to 10 days or until hospital discharge. Clinical response, 60-day survival and adverse effects were the main outcomes of the study. Results In the competing risk survival analysis, patients in the low-dose group had a higher clinical response than the high-dose group when considering death as a competing risk (HR = 2.03, 95% CI: 1.23–3.33, p = 0.03). Also, the survival was significantly longer in the low-dose group than the high-dose group (HR = 0.36, 95% CI = 0.15–0.83, p = 0.02). Leukocytosis and hyperglycemia were the most common side effects of dexamethasone. Although the incidence was not significantly different between the groups, some adverse effects were numerically higher in the intermediate-dose and high-dose groups than in the low-dose group. Conclusions Higher doses of dexamethasone not only failed to improve efficacy but also resulted in an increase in the number of adverse events and worsen survival in hospitalized patients with moderate to severe COVID-19 compared to the low-dose dexamethasone. (IRCT20100228003449N31).
- Open Access
- 1 November 2021
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 15 (6) , 742-749
Distinguishing repeated polymerase chain reaction positivity from re-infections in COVID-19
Background Possibility of reinfection with SARS-CoV-2 changes our view on herd immunity and vaccination and can impact worldwide quarantine policies. We performed real-time polymerase chain reaction (RT-PCR) follow-up studies on recovered patients to assess possible development of reinfections and re-positivity. Methods During a 6-month period, 202 PCR-confirmed recovering COVID-19 patients entered this study. Follow-up RT-PCR tests and symptom assessment were performed 1 month after the initial positive results. Patients who tested negative were tested again 1 and 3 months later. The serum IgG and IgM levels were measured in the last follow-up session. Results In the first two follow-up sessions, 82 patients continued their participation, of which four patients tested positive. In the second follow-up 44 patients participated, three of whom tested positive. None of the patients who tested positive in the first and second follow-up session were symptomatic. In the last session, 32 patients were tested and four patients were positive, three of them were mildly symptomatic and all of them were positive for IgG. Conclusions A positive RT-PCR in a recovering patient may represent reinfection. While we did not have the resources to prove reinfection by genetic sequencing of the infective viruses, we believe presence of mild symptoms in the three patients who tested positive over 100 days after becoming asymptomatic, can be diagnosed as reinfection. The immune response developed during the first episode of infection (e.g., IgG or T-cell mediated responses that were not measured in our study) may have abated the symptoms of the reinfection, without providing complete protection.
- 1 November 2021
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 15 (6) , 742-749
Open AccessDistinguishing repeated polymerase chain reaction positivity from re-infections in COVID-19
Background Possibility of reinfection with SARS-CoV-2 changes our view on herd immunity and vaccination and can impact worldwide quarantine policies. We performed real-time polymerase chain reaction (RT-PCR) follow-up studies on recovered patients to assess possible development of reinfections and re-positivity. Methods During a 6-month period, 202 PCR-confirmed recovering COVID-19 patients entered this study. Follow-up RT-PCR tests and symptom assessment were performed 1 month after the initial positive results. Patients who tested negative were tested again 1 and 3 months later. The serum IgG and IgM levels were measured in the last follow-up session. Results In the first two follow-up sessions, 82 patients continued their participation, of which four patients tested positive. In the second follow-up 44 patients participated, three of whom tested positive. None of the patients who tested positive in the first and second follow-up session were symptomatic. In the last session, 32 patients were tested and four patients were positive, three of them were mildly symptomatic and all of them were positive for IgG. Conclusions A positive RT-PCR in a recovering patient may represent reinfection. While we did not have the resources to prove reinfection by genetic sequencing of the infective viruses, we believe presence of mild symptoms in the three patients who tested positive over 100 days after becoming asymptomatic, can be diagnosed as reinfection. The immune response developed during the first episode of infection (e.g., IgG or T-cell mediated responses that were not measured in our study) may have abated the symptoms of the reinfection, without providing complete protection.
- Open Access
- 21 September 2021
- Published by Springer Nature in Research Square
Outcome of Using Intravenous Immunoglobulin (IVIG) in Critically Ill COVID-19 Patients’: A Retrospective, Multi-Centric Cohort Study
Background: To access the effect of Intravenous immunoglobulin (IVIG) in critically ill corona virus disease 2019 (COVID-19) patients.Method: In this retrospective matched cohort study, records of three tertiary centers with large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using independent t-test and One-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate.Result: The duration of hospitalization in the IVIG group were significantly longer than standard treatment (13.74 days vs. 11.10 days, p<0.05). There was not a significant difference between the two groups in ICU length of stay, number of intubated patients and duration of mechanical ventilation (P>0.05). Also initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (PConclusion: Using IVIG is not beneficial for COVID-19 patients based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation and even mortality rate.
- 21 September 2021
- Published by Springer Nature in Research Square
Open AccessOutcome of Using Intravenous Immunoglobulin (IVIG) in Critically Ill COVID-19 Patients’: A Retrospective, Multi-Centric Cohort Study
Background: To access the effect of Intravenous immunoglobulin (IVIG) in critically ill corona virus disease 2019 (COVID-19) patients.Method: In this retrospective matched cohort study, records of three tertiary centers with large number of COVID-19 admissions were evaluated and used. Based on treatment options, patients were divided into two groups, standard COVID-19 treatment (109 patients) and IVIG treatment (74 patients) patients. Also, the effect of IVIG in different dosages was evaluated. Patients with IVIG treatment were divided into three groups of low (0.25 gr/kg), medium (0.5 gr/kg), and high (1 gr/kg) dose. Data analysis was performed using independent t-test and One-way analysis of variance (ANOVA) to compare the outcomes between two groups, including duration of hospitalization, intensive care unit (ICU) length of stay, and mortality rate.Result: The duration of hospitalization in the IVIG group were significantly longer than standard treatment (13.74 days vs. 11.10 days, p<0.05). There was not a significant difference between the two groups in ICU length of stay, number of intubated patients and duration of mechanical ventilation (P>0.05). Also initial outcomes in IVIG subgroups were compared separately with the standard treatment group. The results indicated that only the duration of hospitalization in the IVIG subgroup with medium dose is significantly longer than the standard treatment group (PConclusion: Using IVIG is not beneficial for COVID-19 patients based on no remarkable differences in duration of hospitalization, ICU length of stay, duration of mechanical ventilation and even mortality rate.